Cancer letters最新文献

Embracing Innovation and Collaboration: A Message from the New Editor-in-Chief. 拥抱创新与合作：新主编的致辞。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-11-16 DOI: 10.1016/j.canlet.2024.217338

Min Li

引用次数: 0

Rebuilding TME may open new doors for improving the prognosis of EGFR mutation patients. 重建 TME 可为改善表皮生长因子受体突变患者的预后打开新的大门。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-11-15 DOI: 10.1016/j.canlet.2024.217323

Rui Han, Conghua Lu, Yong He

引用次数: 0

Single-cell RNA-sequencing of human spleens reveals an IDO-1+ tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individuals 人类脾脏的单细胞 RNA 测序显示，胰腺癌患者体内存在一个 IDO-1+ 耐受性树突状细胞亚群，而正常人体内则不存在该亚群。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-11-14 DOI: 10.1016/j.canlet.2024.217321

Clara S. Mundry , Aleata A. Triplett , Osama Shiraz Shah , Vijender Chaitankar , Kyle L. McAndrews , Quan P. Ly , Jesse L. Cox , Kirsten C. Eberle , Kamiya Mehla , Benjamin J. Swanson , Audrey Lazenby , Kelsey A. Klute , Paul M. Grandgenett , Michael A. Hollingsworth

{"title":"Single-cell RNA-sequencing of human spleens reveals an IDO-1+ tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individuals","authors":"Clara S. Mundry , Aleata A. Triplett , Osama Shiraz Shah , Vijender Chaitankar , Kyle L. McAndrews , Quan P. Ly , Jesse L. Cox , Kirsten C. Eberle , Kamiya Mehla , Benjamin J. Swanson , Audrey Lazenby , Kelsey A. Klute , Paul M. Grandgenett , Michael A. Hollingsworth","doi":"10.1016/j.canlet.2024.217321","DOIUrl":"10.1016/j.canlet.2024.217321","url":null,"abstract":"<div><div>Local and systemic immunosuppression are prominent features of pancreatic cancer, rendering anti-tumor effector cells inactive and immunotherapeutic approaches ineffective. The spleen, an understudied point of antigen-presentation and T cell priming in humans, holds particular importance in pancreatic cancer due to its proximity to the developing tumor. As main effectors of antigen presentation, dendritic cells display antigens to lymphocytes, thereby bridging the innate and adaptive immune response. While tumor-infiltrating anti-inflammatory dendritic cells have been described, splenic dendritic cells have historically just been considered to stimulate the anti-tumor immune response. Here, we describe, for the first time, the presence of an immunosuppressive, tolerogenic IDO1<sup>+</sup> dendritic cell subset in the spleens of pancreatic cancer patients that likely contributes to systemic immunosuppression that is associated with pancreatic ductal adenocarcinoma. Network analysis of scRNA seq data reveals extensive communication networks between the identified tolerogenic DC cluster and numerous immune cell populations in the spleen. Interactions with innate and adaptive immune cells suggest a broad influence on leukocyte trafficking and immune regulation within the spleen microenvironment. The identification of signaling pathways involving AHR and IDO-1, CCL19, NECTIN2, CLEC2D, and others elucidates potential mechanisms underlying the immunosuppressive functions of this cell type.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"607 ","pages":"Article 217321"},"PeriodicalIF":9.1,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

"Towards melanoma in situ vaccination with multiple ultra-narrow X-ray beams". "利用多束超窄 X 射线实现黑色素瘤原位接种"。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-11-13 DOI: 10.1016/j.canlet.2024.217326

Verdiana Trappetti, Cristian Fernández-Palomo, Prateek Arora, Marine Potez, Paolo Pellicioli, Jennifer Fazzari, Nahoko Shintani, Ismael Sanchez-Gonzalez, Cheuk Ting Wu, Bettina de Breuyn Dietler, Nadia Mercader-Huber, Olga A Martin, Stephan von Gunten, Vladislav Volarevic, Valentin Djonov

{"title":"\"Towards melanoma in situ vaccination with multiple ultra-narrow X-ray beams\".","authors":"Verdiana Trappetti, Cristian Fernández-Palomo, Prateek Arora, Marine Potez, Paolo Pellicioli, Jennifer Fazzari, Nahoko Shintani, Ismael Sanchez-Gonzalez, Cheuk Ting Wu, Bettina de Breuyn Dietler, Nadia Mercader-Huber, Olga A Martin, Stephan von Gunten, Vladislav Volarevic, Valentin Djonov","doi":"10.1016/j.canlet.2024.217326","DOIUrl":"https://doi.org/10.1016/j.canlet.2024.217326","url":null,"abstract":"<p><p>Despite the recent progress, current treatment modalities are not able to eradicate cancer. We show that Microbeam Radiotherapy (MRT), an innovative type of Spatially Fractionated Radiotherapy, can control murine melanoma by activating the host's own immune system. The beneficial effects are very pronounced in comparison to uniform radiotherapy, traditionally employed in the clinic. Our results displayed that MRT increased antigen presentation, activating Cytotoxic T Lymphocytes (CTLs) which are essential to MRT's treatment efficacy in melanoma. Depletion of CTLs abrogated treatment response. Multiplex nucleic acid hybridization technology revealed key features of lymphocyte populations such as proliferation, differentiation, and ligand-receptor interactions. In addition, CTLs were shown to be essential for locoregional metastatic control and systemic abscopal effects confirmed by activation of antigen presenting cells and CTL trafficking in the tumour-draining lymph nodes. MRT induces a robust antitumour immune response, matching the characteristics of in situ vaccination, that could be exploited to treat a variety of treatment-resistant malignancies.</p>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":" ","pages":"217326"},"PeriodicalIF":9.1,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Precision meets repurposing: Innovative approaches in human papillomavirus and Epstein-Barr virus-driven cancer therapy. 精准与再利用：人类乳头状瘤病毒和 Epstein-Barr 病毒驱动的癌症疗法中的创新方法。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-11-08 DOI: 10.1016/j.canlet.2024.217318

Queenie Fernandes

{"title":"Precision meets repurposing: Innovative approaches in human papillomavirus and Epstein-Barr virus-driven cancer therapy.","authors":"Queenie Fernandes","doi":"10.1016/j.canlet.2024.217318","DOIUrl":"10.1016/j.canlet.2024.217318","url":null,"abstract":"<p><p>Viral malignancies represent a distinct entity among cancers. Oncoviruses like the Human Papilloma Virus (HPV) and the Epstein Barr Virus (EBV) are highly potent inducers of oncogenic transformation leading to tumor development. HPV and EBV are known to be increasingly involved in the pathogenesis of various classes of cancers like cervical, head and neck, colorectal, breast, oral and anogenitial. Therapeutic vaccines directed at such oncoviruses, often fail to unleash the desired immune response against the tumor. This is largely due to the immunosuppressive microenvironment of the virus-induced tumors. Consequently, metronomic chemotherapies administered in conjunction with therapeutic viral vaccines have considerably enhanced the antitumor activity of these vaccines. Moreover, given the unique attributes of HPV and EBV-associated cancers, therapeutic agents directly targeting the oncoproteins of these viruses are still obscure. In this light, an increasing number of reports have evidenced the repurposing of drugs for therapeutic benefits in such cancers. This work delineates the significance and implications of metronomic chemotherapy and drug repurposing in HPV and EBV-associated cancers.</p>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":" ","pages":"217318"},"PeriodicalIF":9.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sufficient Life Expectancy as an Eligibility Criterion in Cancer Clinical Trials. 将足够的预期寿命作为癌症临床试验的资格标准。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-11-08 DOI: 10.1016/j.canlet.2024.217322

Nicole D Agaronnik, Lisa I Iezzoni

引用次数: 0

Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma 泰拉格司他作为顺铂的放射增敏剂替代品，用于治疗头颈部鳞状细胞癌。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-11-01 DOI: 10.1016/j.canlet.2024.217320

Julianna Korns , Christina A. Wicker , Maria Lehn , Shreya Shyamsunder , Samuel Thompson , Carissa Lester , Trisha M. Wise-Draper , Susan E. Waltz , Vinita Takiar

{"title":"Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma","authors":"Julianna Korns , Christina A. Wicker , Maria Lehn , Shreya Shyamsunder , Samuel Thompson , Carissa Lester , Trisha M. Wise-Draper , Susan E. Waltz , Vinita Takiar","doi":"10.1016/j.canlet.2024.217320","DOIUrl":"10.1016/j.canlet.2024.217320","url":null,"abstract":"<div><div>The efficacy of radiation treatment (RT) of head and neck squamous cell carcinoma (HNSCC) is limited by radioresistance and the toxicity of FDA approved radiosensitizers. In extension to our previous research where we demonstrated that telaglenastat (CB839) increased efficacy of RT in <em>in vitro</em> and <em>in vivo</em> HNSCC models, here, we examine the radiosensitizing effects of telaglenastat in comparison to cisplatin's, as cisplatin is currently the standard of care for concurrent therapy. Combination of telaglenastat with RT reduced tumor volume in a HNSCC patient derived xenograft mouse model. The efficacy of telaglenastat with RT in reducing cell survival and increasing apoptosis was similar if not greater than that of cisplatin with RT in Cal27 and HN5 HNSCC cells. The addition of telaglenastat increased reactive oxygen species and reduced the antioxidant glutathione in both Cal27 and HN5 cells. Reverse Phase Protein Array analyses revealed alterations in cell death and DNA damage response proteins. This study provides the scientific underpinnings for the use of telaglenastat as a radiosensitizer in the treatment of HNSCC either as an alternative to cisplatin or in cisplatin-ineligible patients.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"606 ","pages":"Article 217320"},"PeriodicalIF":9.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engraftment of a Surrogate Antigen onto Tumor Cell Surface via pHLIP Peptide to Universally Target CAR-T Cell Therapy to Solid Tumors. 通过 pHLIP 肽在肿瘤细胞表面移植替代抗原，使 CAR-T 细胞疗法普遍针对实体瘤。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-11-01 DOI: 10.1016/j.canlet.2024.217319

Yan-Ting Zhang, Xinping Fu, Jane Jing Ting Lim, Shaun Xiaoliu Zhang

{"title":"Engraftment of a Surrogate Antigen onto Tumor Cell Surface via pHLIP Peptide to Universally Target CAR-T Cell Therapy to Solid Tumors.","authors":"Yan-Ting Zhang, Xinping Fu, Jane Jing Ting Lim, Shaun Xiaoliu Zhang","doi":"10.1016/j.canlet.2024.217319","DOIUrl":"https://doi.org/10.1016/j.canlet.2024.217319","url":null,"abstract":"<p><p>CAR-T cells and monoclonal antibodies (mAbs) are immunotherapeutics that have shown efficacies against certain malignancies. However, their broad application is hindered by the scarcity of tumor-associated antigens on tumor cell surfaces. Previous investigations unveiled the unique capacity of pH-low insertion peptide (pHLIP) to anchor to plasma membranes under acidic conditions. Considering that an acidic tumor microenvironment is a hallmark of solid tumors, we engineered a novel peptide, Myc-pHLIP, by tethering a surrogate epitope tag, the c-Myc-tag, to pHLIP. We evaluated the efficiency of Myc-pHLIP in inserting the artificial c-Myc-tag onto the plasma membrane of malignant cells and determined if this engraftment could convert it into a therapeutic target for CAR-T cells or mAbs. Our in vitro experiments demonstrated that incubating Myc-pHLIP with tumor cells in acidic media triggered significant killing by either Myc-targeted CAR-T cells (Myc-CAR-T), or by an anti-Myc mAb in the presence of NK cells. In vivo studies demonstrated substantial antitumor effects with sequential administration of Myc-pHLIP followed by either Myc-CAR-T or Myc-mAb. These findings establish that Myc-pHLIP has the potential to act as a universal surrogate tumor antigen capable of directing CAR-T cells or mAbs to treat any solid tumors by concurrently targeting both malignant and stromal cells.</p>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":" ","pages":"217319"},"PeriodicalIF":9.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations 免疫检查点抑制剂作为无驱动基因突变的 IV 期 NSCLC 患者脑转移的一线治疗方法。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-11-01 DOI: 10.1016/j.canlet.2024.217317

Guillermo Suay , Juan-Carlos Garcia-Cañaveras , Francisco Aparisi , José Garcia , Oscar Juan-Vidal , Agustín Lahoz

{"title":"Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations","authors":"Guillermo Suay , Juan-Carlos Garcia-Cañaveras , Francisco Aparisi , José Garcia , Oscar Juan-Vidal , Agustín Lahoz","doi":"10.1016/j.canlet.2024.217317","DOIUrl":"10.1016/j.canlet.2024.217317","url":null,"abstract":"<div><div>Immune checkpoint inhibitors (ICI) therapy with or without chemotherapy has been established as the first-line treatment for patients with non-oncogene addicted advanced Non-Small Cell Lung Cancer (NSCLC). Yet some clinical settings, such as the treatment sequence in patients with brain metastases, have barely been evidenced. Although ICIs cannot directly cross the blood-brain barrier (BBB), evidence suggests that BBB damage could allow ICIs into the central nervous system, or that they can have an indirect effect on the tumor immune microenvironment (TIME) and cause an anti-tumor response. Pivotal phase III trials have included a highly selected population but offer few data on these patients. Here we first review how ICIs can indirectly shape the brain metastases microenvironment through different mechanisms, and some possible causes of ICIs resistance. We also analyze the evidence reported in pivotal phase III trials and phase II trials focused on NSCLC brain metastases for first-line treatment, and the evidence for upfront or delayed local brain therapy. Finally, we discuss the best evidence-based approach to treat NSCLC patients with brain metastases and propose future research.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"606 ","pages":"Article 217317"},"PeriodicalIF":9.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142567258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical challenges in prostate cancer management: Metastatic bone-tropism and the role of circulating tumor cells 前列腺癌治疗的临床挑战：转移性骨质增生和循环肿瘤细胞的作用。

IF 9.1 1区医学

Cancer letters Pub Date : 2024-10-31 DOI: 10.1016/j.canlet.2024.217310

Gayathri K. Guruvayurappan , Tina Frankenbach-Désor , Markus Laubach , Alexander Klein , Michael von Bergwelt-Baildon , Monica Cusan , Attila Aszodi , Boris M. Holzapfel , Wolfgang Böcker , Susanne Mayer-Wagner

{"title":"Clinical challenges in prostate cancer management: Metastatic bone-tropism and the role of circulating tumor cells","authors":"Gayathri K. Guruvayurappan , Tina Frankenbach-Désor , Markus Laubach , Alexander Klein , Michael von Bergwelt-Baildon , Monica Cusan , Attila Aszodi , Boris M. Holzapfel , Wolfgang Böcker , Susanne Mayer-Wagner","doi":"10.1016/j.canlet.2024.217310","DOIUrl":"10.1016/j.canlet.2024.217310","url":null,"abstract":"<div><div>Prostate cancer (PCa) metastasis is one of the leading causes of cancer-related mortality in men worldwide, primarily due to its tendency to metastasize, with bones of axial skeleton being the favored target-site. PCa bone-metastasis (PCa-BM) presents significant clinical challenges, especially by the weakening of bone architecture, majorly due to the formation of osteoblastic lesions, leading to severe bone fractures. Another complication is that the disease predominantly affects elderly men. Further exploration is required to understand how the circulating tumor cells (CTCs) adapt to varying microenvironments and other biomechanical stresses encountered during the sequential steps in metastasis, finally resulting in colonization specifically in the bone niche, in PCa-BM.</div><div>Deciphering how CTCs encounter and adapt to different biochemical, biomechanical and microenvironmental factors may improve the prospects of PCa diagnosis, development of novel therapeutics and prognosis. Moreover, the knowledge developed is expected to have broader implications for cancer research, paving the way for better therapeutic strategies and targeted therapies in the realm of metastatic cancer progression across different types of cancers.</div><div>Our review begins with analyzing the challenges in PCa diagnosis, treatment and management, and delves into the formation and dynamics of CTCs, highlighting their role in PCa metastasis and bone-tropism. We further explore the pivotal role of individual factors in dictating the predisposition of tumors to metastasize to specific secondary sites, such as the noteworthy tendency of PCa bone-metastasis. Finally, we highlight the unresolved questions and potential avenues for further exploration.</div></div>","PeriodicalId":9506,"journal":{"name":"Cancer letters","volume":"606 ","pages":"Article 217310"},"PeriodicalIF":9.1,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0